08:39 , Apr 3, 2019 |  BC Extra  |  Financial News

AgomAb emerges from stealth with €21M series A

Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration. AgomAb Therapeutics...
22:57 , May 16, 2018 |  BC Extra  |  Company News

Management tracks: Novartis, Aileron

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...
16:34 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

AM-Pharma's Phase II sepsis readout triggers Pfizer's takeout option

AM-Pharma B.V. (Bunnik, the Netherlands) reported mixed data from the Phase II STOP-AKI trial of recAP to treat sepsis-associated acute kidney injury (AKI). The readout marks the start of an option period under which Pfizer...
21:38 , Mar 9, 2018 |  BC Extra  |  Clinical News

AM-Pharma's Phase II sepsis readout triggers Pfizer's takeout option

AM-Pharma B.V. (Bunnik, the Netherlands) reported mixed data on Friday from the Phase II STOP-AKI trial of recAP to treat sepsis-associated acute kidney injury (AKI). The readout marks the start of an option period under...
19:51 , May 25, 2017 |  BC Week In Review  |  Clinical News

AM-Pharma completes Phase II enrollment of recAP in AKI

AM-Pharma B.V. (Bunnik, the Netherlands) completed enrollment of 301 patients in the Phase II STOP-AKI trial of recAP (recombinant alkaline phosphatase) to treat sepsis-associated acute kidney injury (AKI). The double-blind, placebo-controlled, international trial is evaluating...
07:00 , Sep 5, 2016 |  BioCentury  |  Strategy

Back to School: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
07:00 , May 18, 2015 |  BC Week In Review  |  Company News

AM-Pharma, Pfizer deal

Pfizer purchased a 17.5% equity stake in AM-Pharma and received an option acquire the remainder of the company. The option is exercisable upon completion of a Phase II trial of AM-Pharma’s recAP recombinant alkaline phosphatase...
02:17 , May 12, 2015 |  BC Extra  |  Company News

Pfizer, AM-Pharma in equity/option deal

Pfizer Inc. (NYSE:PFE) purchased an equity stake in renal company AM-Pharma B.V. (Bunnik, the Netherlands) and obtained an exclusive option to acquire the remainder of the company. Pfizer can exercise the option when an ongoing...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Clinical News

RecAP: Phase II started

AM-Pharma began the double-blind, placebo-controlled, international Phase II STOP-AKI trial to evaluate 0.4, 0.8 and 1.6 mg/kg IV RecAP once daily for 3 days in about 290 patients with sepsis-associated AKI. A dose-finding part will...